NASDAQ: KZIAKazia Therapeutics Ltd Stock
$0.38+0.00 (+0%)
Updated Apr 22, 2024
KZIA Price
$0.38
Fair Value Price
$0.01
Market Cap
$9.94M
52 Week Low
$0.19
52 Week High
$1.49
P/E
-1.03x
P/B
2.87x
P/S
640.39x
PEG
N/A
Dividend Yield
N/A
Revenue
$15.13k
Earnings
-$10.68M
Gross Margin
100%
Operating Margin
-69,438.83%
Profit Margin
-68,256.8%
Debt to Equity
3.63
Operating Cash Flow
-$9M
Beta
0.53
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
KZIA Overview
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how KZIA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
KZIA ($0.38) is overvalued by 3,040.59% relative to our estimate of its Fair Value price of $0.01 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
KZIA ($0.38) is not significantly undervalued (3,040.59%) relative to our estimate of its Fair Value price of $0.01 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
KZIA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more KZIA due diligence checks available for Premium users.
Be the first to know about important KZIA news, forecast changes, insider trades & much more!
KZIA News
Valuation
KZIA fair value
Fair Value of KZIA stock based on Discounted Cash Flow (DCF)
Price
$0.38
Fair Value
$0.01
Overvalued by
3,065.58%
KZIA ($0.38) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
KZIA ($0.38) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
KZIA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
KZIA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.03x
Industry
16.21x
Market
41x
KZIA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.87x
Industry
5.82x
KZIA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
KZIA's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
KZIA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
KZIA's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$16.6M
Liabilities
$13.0M
Debt to equity
3.63
KZIA's short-term liabilities ($7.46M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KZIA's short-term assets ($5.27M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KZIA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
KZIA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
KZIA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
KZIA vs Biotech Stocks
Kazia Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.